Alnylam Q1 Revenue Surges 96% to $1.17B, Reports $206M Net Income
ALNY sits 33% above its 52-week low of $245.96.
Summary
Alnylam Pharmaceuticals reported robust first-quarter 2026 financial results, with total revenues soaring 96% year-over-year to $1.17 billion and GAAP net income reaching $206 million. Net product revenues, primarily driven by AMVUTTRA, surged 121% to $1.036 billion. This strong performance reinforces the company's positive trajectory, following its achievement of its first annual net income in 2025, and signals sustained commercial execution and pipeline success. The significant growth and profitability are highly material for investors, likely impacting positioning decisions. The company also reiterated its full-year 2026 guidance, and traders will be monitoring further pipeline advancements, including the expanded TRITON-CM enrollment and anticipated clinical readouts in the second half of 2026.
At the time of this announcement, ALNY was trading at $327.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.2B. The 52-week trading range was $245.96 to $495.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.